Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 May 14;100(19):e25852.
doi: 10.1097/MD.0000000000025852.

Combined therapy of hypertensive nephropathy with ginkgo leaf extract and dipyridamole injection and antihypertensive drugs: A systematic review and meta-analysis

Affiliations
Meta-Analysis

Combined therapy of hypertensive nephropathy with ginkgo leaf extract and dipyridamole injection and antihypertensive drugs: A systematic review and meta-analysis

Dinala Jialiken et al. Medicine (Baltimore). .

Abstract

Background: In recent years, the incidence rate of hypertensive nephropathy has been increasing quickly, which has been a major threat to people's health. Renin-angiotensin-aldosterone system blockers have certain curative effects. However, there are some patients having serious adverse reactions, and the benefit population is limited, so the treatment of hypertensive renal damage is necessary to have beneficial supplement. More and more clinical studies have shown that ginkgo leaf extract and dipyridamole injection (GDI) combined with antihypertensive drugs has achieved good results in the treatment of hypertensive renal damage. It is supposed to be a supplementary treatment in hypertensive nephropathy.

Objectives: To systematically assess the efficacy and safety of GDI combined with antihypertensive drugs on hypertensive renal injury.

Methods: Seven databases including PubMed, Cochrane Library, Embase, Wanfang database, China biomedical literature service system (Sino Med), VIP Chinese Sci-tech journal database (VIP), and China national knowledge internet (CNKI) were retrieved to collect randomized controlled trials (RCTs) in the experimental group containing combined therapy of hypertensive nephropathy with GDI and antihypertensive drugs. The retrieval time was from the establishment of database to July 8, 2020. Two researchers independently selected literature, extracted data, and evaluated the risk of bias in the study. The methodological quality was evaluated with Cochrane handbook and meta-analysis was performed with Stata 14.0 software.

Results: Eight studies were included in this study which involved 556 patients. The meta-analyses indicated that, compared with using antihypertensive drugs alone, combined treatment of GDI with antihypertensive drugs can decrease 24-hour urinary total protein (weighted mean difference [WMD] -0.61, 95% confidence interval [CI]: -0.82, -0.39; k = 6, P ≤ .001), blood urea nitrogen (WMD -1.27, 95% CI: -2.45, -0.10; k = 6, P = .033, serum creatinine (WMD -29.50, 95% CI: -56.44, -2.56; number of estimates [k] = 6, P = .032).

Conclusions: Our meta-analyses showed that GDI combined with antihypertensive drugs can improve the renal function of hypertensive patients with renal injury.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow-process diagram of literature retrieval.
Figure 2
Figure 2
Risk of bias.
Figure 3
Figure 3
Risk of bias summary and graph.
Figure 4
Figure 4
Forest plot of 24 h UTP of Ginkgo leaf extract and dipyridamole injection combined with regular treatment versus regular treatment. 24 h UTP = 24 hours urinary total protein.
Figure 5
Figure 5
Forest plot of BUN of Ginkgo leaf extract and dipyridamole injection combined with regular treatment versus regular treatment. BUN = blood urea nitrogen.
Figure 6
Figure 6
Forest plot of Scr of Ginkgo leaf extract and dipyridamole injection combined with regular treatment versus regular treatment. Scr = serum creatinine.

References

    1. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380:1649–61. - PMC - PubMed
    1. Du H. Etiology analysis of patients with end-stage renal disease. China Pract Med 2016;24:52–3.
    1. Fathallah-Shaykh SA, Flynn JT, Pierce CB, et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol 2015;10:571–7. - PMC - PubMed
    1. Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015;65:878–88. - PMC - PubMed
    1. Vidi Smitha R. Role of hypertension in progression of chronic kidney disease in children. Curr Opin Pediatr 2018;30:247–51. - PubMed

MeSH terms

Supplementary concepts